The total number of records retrieved from this search are 36. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_276	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result90% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_277	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result90% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_278	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result85% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_279	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result83% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_280	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result92% cancer cell viability at 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_281	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result94% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_282	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result86% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_291	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result91% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_292	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result85% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_293	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result65% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_294	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result56% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_295	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result92% cancer cell viability at 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_296	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result81% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_297	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result61% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_301	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result100% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_302	Virus nameAdenovirus	Virus strainAd.IL3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-IL3 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result90% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_303	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result80% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_304	Virus nameAdenovirus	Virus strainAd.IL3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-IL3 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result100% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_310	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result82% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_311	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result58% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_312	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result52% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_313	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result38% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_768	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result80% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_769	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result60% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_770	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result50% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_771	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result46% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_772	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result40% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_798	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result80% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_799	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result40% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_800	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result32% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_801	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result25% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_802	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman acute promyelocytic leukemic cell line	Cell lineHL-60	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result20% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_2903	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayLuminiscent cell viability assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_2904	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayLuminiscent cell viability assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_2905	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles in combination with mumps	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineHL-60	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayLuminiscent cell viability assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viabiity	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_4316	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman acute promyelocytic leukemia	Cell lineHL-60	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result85.2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347